We are proud to be involved in several clinical trials that bring state-of-the-art technology to our patients. Our clinical studies coordinator is Lisa Navarro, and you can contact her for more details about our studies.
Below is a list of our current trials:
Do You Need Cataract Surgery?
Learn more about a new clinical study at newcataractstudy.com
If you have been diagnosed with cataracts in both eyes, you may qualify for a study that involves the Light Adjustable Lens™.
Call our office to schedule an appointment.
Light Adjustable Lens new FDA Study
Contact: Lisa Navarro
210-614-3600 ext. 118
Johnson & Johnson Vision ANCORA Study
This study is a post-approval survey in patients undergoing cataract surgery with the Symfony Toric IOL. In this study, patients are subjected to questionnaires and are required to make post-op visits. Patients will be compensated for their time.
Complete inclusion and exclusion criteria are found Here
Contact: Lisa Navarro
210-614-3600 ext. 118
Closed Trials
Johnson & Johnson Vision BRAVO Study (Closed)
This study involves the next-generation extended depth-of-focus intraocular lenses for cataract patients. In this study, patients are subjected to questionnaires and are required to make post-op visits. Patients will be compensated for their time.
Contact: Lisa Navarro
210-614-3600 ext. 118
RxSight Light Adjustable Lens (Closed)
This study involves the placement of the FDA-approved RxSight Light Adjustable Lens in cataract patients with a history of refractive surgery (LASIK or PRK).
Complete inclusion and exclusion criteria are found Here
Main Contact: Lisa Navarro
210-614-3600 ext. 118
Avedro Epithelial-On Cross-linking (Closed)
Over the last decade, corneal cross-linking (CXL) has been shown to halt the progression of keratoconus, but the “gold standard,” only FDA-approved treatment is epithelium-off cross-linking. We have been performing this technique for over five years, but there are risks associated with the procedure, including significant post-operative pain, haze, and delayed healing.
Thus, we are excited to be part of this groundbreaking clinical trial that may lead to FDA approval for epithelial-on cross-linking.
Complete inclusion and exclusion criteria are found Here
Main Contact: Lisa Navarro
210-614-3600 ext. 118
Johnson & Johnson Vision Multifocal IOL Study (Closed)
This study involves the next-generation extended depth-of-focus intraocular lenses for cataract patients. In this study, patients are subjected to questionnaires and are required to make post-op visits. Patients will be compensated for their time.
Contact: Lisa Navarro
210-614-3600 ext. 118
Allergan Bimatoprost Study (Closed)
This study involves the insertion of a microscopic “dot” into the anterior chamber, or “front part of the eye,” where it slowly releases medicine to keep the eye pressure under control without having to use eye drops! If you have glaucoma or you know somebody who has glaucoma (high eye pressure), please contact Lisa Navarro at (210) 614-3600 to enroll in our study.
Ophtec Artisan Aphakic IOL (Closed)
This study deals with the implantation of an artificial lens in patients who are aphakic or who have problems with their current artificial lens. This special implant clips to the iris, eliminating the need for more invasive surgery and improving the patient’s vision.
J&J Vision DENALI Toric IOL Study (Closed)
This study revolves around astigmatism correction at the time of cataract surgery. Patients with high levels of astigmatism can benefit from a specialized, “toric” IOL that neutralizes corneal astigmatism. In this study, patients are subjected to a questionnaire about their vision.
Calhoun Light Adjustable Lens (Closed)
Cataract surgery involves the removal of the cloudy, natural lens, and replacement with an artificial lens. In this clinical trial, we were one of less than 20 sites in the country to use the Calhoun LAL, or light adjustable lens. This remarkable technology allowed us to adjust the prescription of the IOL without additional surgery. The technology has been submitted for FDA approval and has been named RXSIGHT
Cross-Linking for Keratoconus and Corneal Ectasia (Closed)
After a long wait, corneal cross-linking, or CXL, has been FDA approved! We were involved in three FDA trials related to the treatment of keratoconus and corneal ectasia. Please see our website section about keratoconus treatments for more details about how to arrange a consultation to consider corneal cross-linking.
- Ophtec 311 Artificial Iris (Closed)
- Corneal Preservation Time Study (Closed)
- Diabetes Endothelial Keratoplasty Study (Pending)
- FECD Genetics Multi-Center Study Group (Closed)
These studies deal with corneal transplants, specifically DSEK and DMEK, as well as eye banking. If you have to Fuch’s Corneal Dystrophy or Corneal Edema, you may be asked to participate in these trials, which are sponsored by the National Institutes of Health, or NIH. The goals of these trials are to better understand the genetics behind common corneal dystrophies, as well as to characterize the donor factors that best predict success in corneal transplants.
To learn more about Focal Point Vision, or to schedule an appointment, please contact us today!
